The CRISPR Delivery Problem That's Harder Than Gene Editing Itself
Gene editing precision means nothing if you can't get the scissors to the right cells
Epigenetic Drugs Reset Cancer Cells to Normal—But Precision Remains Elusive
When cancer cells are misprogrammed rather than broken, medicine attempts to restore the code—but editing thousands of genes at once has consequences
Why Organ-on-Chip Technology Will Transform Drug Safety Testing
Microphysiological systems that recreate human organ complexity are revolutionizing how we predict drug toxicity before clinical trials.
Why mRNA Vaccines Work Faster Than Anyone Predicted—And What Comes Next
Decades of molecular problem-solving converged to enable vaccines in weeks—and unlock a programmable platform for therapeutic protein production.
Base Editing Surpasses CRISPR in Safety—But Brings Its Own Genomic Risks
Newer gene editing tools avoid DNA breaks but introduce distinct risks that demand careful therapeutic matching.
AI Pathology Detects Cancer Origins Human Eyes Miss—But Trust Remains the Barrier
Deep learning sees cancer patterns invisible to human eyes, but clinical adoption awaits solutions to trust, liability, and regulatory uncertainty
Antisense Oligonucleotides Are Silencing the Undruggable—Here's Their Limit
Chemically modified nucleic acids are unlocking previously inaccessible therapeutic targets, but tissue delivery constraints define their current therapeutic ceiling.
Tumor-Infiltrating Lymphocyte Therapy Outperforms CAR-T in Solid Tumors—Here's Why
How naturally tumor-adapted lymphocytes solve the trafficking, targeting, and persistence problems that continue to limit engineered CAR-T approaches against epithelial cancers.
How Spatial Transcriptomics Reveals Why Tumors Resist Drugs
Mapping gene expression within tissue architecture exposes how tumor neighborhoods create protected havens where cancer cells survive our best therapies
Why Gene Therapy Prices Exceed Chemotherapy Lifetime Costs—And Why That Math May Actually Work
Exploring how healthcare systems are restructuring payment flows and risk distribution to unlock curative gene therapies that offer transformative value but demand unprecedented upfront investment.
The Microbiome-Immunotherapy Connection Oncologists Can't Ignore
How the trillions of bacteria in your gut are determining whether cancer immunotherapy saves your life or fails entirely.
Liquid Biopsies Are Rewriting Cancer Staging—Here's What Oncologists Actually See
How circulating tumor DNA is transforming cancer monitoring from periodic snapshots into continuous molecular surveillance of disease biology
Why CAR-T Cells Exhaust Before Cancer Dies—And How Scientists Are Fixing It
Inside the molecular battle to keep engineered immune cells fighting when tumors try to silence them—and the synthetic biology solutions emerging from exhaustion research.
Antibody-Drug Conjugates Achieve What Chemotherapy Alone Never Could
Precision-guided cytotoxic missiles are redefining cancer treatment by achieving efficacy levels that systemic chemotherapy could never safely reach.